Low-Dose GLP-1 Therapy for MCAS and Autoimmune Conditions: How Compliant Compounding Works in Texas in 2026

By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

If you follow health news, you know that compounded GLP-1 medications have been at the center of an FDA enforcement storm. The shortage-era days of $199-a-month compounded semaglutide from telehealth weight-loss platforms are over, and for good reason: once the FDA declared the semaglutide and tirzepatide shortages resolved in 2024–2025, mass-producing copies of Ozempic, Wegovy, Mounjaro, and Zepbound became legally impermissible.

So why would a careful, compliance-focused physician still prescribe any compounded GLP-1 in 2026?

Because there is one narrow, legitimate, well-documented lane that remains — and it happens to be exactly the lane that matters for clients with mast cell activation syndrome (MCAS), autoimmune conditions, and chronic inflammatory illness: doses so low that no commercial product can safely deliver them.

This article explains the clinical rationale, the federal and Texas regulatory framework, and the strict guardrails I use in my telemedicine practice at www.directintegrativecare.com. It is educational content, not legal advice — and it describes a deliberately conservative approach.

Why Low-Dose GLP-1s for MCAS and Autoimmune Conditions?

GLP-1 receptor agonists were developed for diabetes and obesity, but a growing body of research points to effects that have nothing to do with the scale: modulation of neuroinflammation, reduction of pro-inflammatory cytokines, effects on microglial activation, and improvement in conditions with an inflammatory or dysautonomic component. In the integrative medicine community, clinicians working with MCAS, POTS, hypermobility spectrum disorders, and Long COVID have taken notice — much as we did with low-dose naltrexone (LDN) years ago.

The key phrase is low dose. The goal in this context is not appetite suppression or weight loss. It is gentle immune and inflammatory modulation in clients who are often exquisitely medication-sensitive. Many MCAS clients cannot tolerate a standard starting dose of anything — they need to begin at a fraction of the lowest commercial dose and titrate slowly, watching for reactions.

That clinical reality is what creates both the medical necessity and the legal basis for compounding.

The Commercial Dosing Problem

Here is the practical issue. The lowest commercially available doses are:

Semaglutide (Wegovy) starts at 0.25 mg weekly. Tirzepatide (Zepbound) starts at 2.5 mg weekly. For a medication-sensitive MCAS client, an appropriate starting dose may be 0.1–0.2 mg of tirzepatide — roughly 1/12th to 1/25th of the lowest manufactured dose.

Could you simply draw a partial dose from a commercial vial? In theory. In practice, commercial single-dose vials are concentrated (tirzepatide at 5 mg/mL), which means a 0.1 mg dose is about 2 units on a U-100 insulin syringe — at the very edge of what a client can measure reliably at home. Commercial vials are also single-dose and preservative-free, creating sterility and waste problems when a client uses a tiny fraction and would need to discard the rest, week after week.

A compounded preparation at a dilute concentration (for example, 0.5–1 mg/mL) solves the accuracy problem, allows safe home administration, and enables the slow micro-titration these clients require. The commercially available product cannot do the job at these doses. That is the entire foundation of compliant compounding in this scenario.

The Federal Framework: "Essentially a Copy"

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a patient-specific medication — but it may not compound what the FDA calls "essentially a copy" of a commercially available FDA-approved drug, unless the prescriber documents that a specific change produces a significant clinical difference for that individual patient.

Three points define the current landscape:

The shortage exception is gone. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, with phased enforcement deadlines for compounders to wind down, and court challenges by the Outsourcing Facilities Association failed to secure preliminary injunctions. Routine compounding of standard-dose GLP-1s for cost or convenience is no longer legal.

The door is closing on 503B facilities. On April 30, 2026, the FDA proposed removing semaglutide and tirzepatide from the 503B outsourcing facility bulks list, with the public comment period closing June 29, 2026. Large-scale outsourcing facilities are being pushed out of this space entirely.

The patient-specific 503A exception remains. A 503A pharmacy may still compound for an individual patient when the prescriber documents that a modification — a different strength, a different concentration, removal of an allergenic excipient — is medically necessary for that client. Cost savings is explicitly not a valid basis. A dose strength that does not exist commercially, prescribed because the client clinically cannot tolerate the lowest manufactured dose, is precisely the kind of clinical difference the statute contemplates.

This is why my practice's model is built exclusively around the 503A patient-specific pathway, with a prescription written for one named client, at one specific sub-commercial dose, with the clinical rationale documented in the chart every time.

The Texas Layer: What the State Requires

Texas adds its own requirements on top of federal law, and the Texas State Board of Pharmacy (TSBP) is one of the more active enforcement boards in the country.

Pharmacy permits. A compounded injectable GLP-1 is a sterile preparation. An in-state Texas pharmacy compounding it must hold a Class A-S (sterile compounding) permit. Critically, an out-of-state pharmacy shipping sterile compounded preparations to Texas residents must hold a Class E-S permit — a standard Class E nonresident permit explicitly excludes dispensing or shipping sterile compounded preparations to Texas residents, and Class E-S licensure requires board inspection to ensure the pharmacy meets Texas sterile compounding standards. Before any prescription is sent, the pharmacy's permit status can and should be verified through TSBP's public license lookup at pharmacy.texas.gov.

Telemedicine standards. Texas requires a valid practitioner–client relationship established through appropriate evaluation. In my practice, every client considering low-dose GLP-1 therapy is evaluated through a synchronous video visit with a full history, medication review, and discussion of alternatives — never an asynchronous questionnaire.

Base-form API only. Texas regulators have pursued enforcement against pharmacies using salt forms of these peptides. Only base-form semaglutide or tirzepatide, from a pharmacy that can produce a Certificate of Analysis documenting identity, potency, and sterility, is acceptable.

No additive workarounds. Some pharmacies have marketed GLP-1s mixed with B12 or amino acids as a way around the "essentially a copy" rule. The FDA has rejected the idea that adding extras automatically makes a product meaningfully different, and emerging chemistry research has raised questions about peptide–additive interactions in some of these formulations. My practice prescribes the peptide alone, at the dilute concentration the client actually needs — the dose itself is the medical necessity, not a marketing additive.

The Guardrail That Matters Most: A Hard Stop at Commercial Doses

Here is the policy that makes this model fundamentally different from weight-loss GLP-1 prescribing — and, frankly, what makes it defensible:

I only prescribe compounded GLP-1 doses that are not commercially available. The moment a client titrates up to a commercially manufactured dose, compounding ends.

If a client on low-dose tirzepatide for MCAS eventually reaches 2.5 mg weekly, the medical-necessity rationale for compounding no longer exists — the FDA-approved product now serves them. At that point, the client transitions to the commercial product, and because standard-dose GLP-1 therapy for weight management is outside the scope of my practice, clients who want to continue on conventional dosing are referred to a provider whose practice is built for that.

This is not a loophole being stretched; it is the opposite. The compliance question the FDA asks is, "Why couldn't the approved product meet this patient's need?" In my model, the answer is documented at every visit — and when the answer stops being true, the compounded prescription stops.

What This Looks Like in Practice

For clients of www.directintegrativecare.com, the pathway looks like this. First, a comprehensive synchronous telemedicine evaluation establishes the diagnosis (MCAS, autoimmune, or inflammatory condition), reviews prior medication sensitivities, and documents why the lowest commercial dose is clinically inappropriate for that individual. Second, informed consent covers the off-label indication, the compounded (non-FDA-approved) nature of the preparation, the dosing precision rationale, the limited evidence base at micro-doses, and the planned endpoint. Third, a patient-specific prescription is sent to a verified 503A pharmacy — Texas Class A-S, or Class E-S if out of state — with PCAB accreditation, USP <797> compliance, base-form API, and batch Certificates of Analysis. Fourth, close follow-up documents response, tolerance, and the continuing (or ending) medical necessity at each titration step.

Slow, individualized, documented, and self-limiting. That is what compliant looks like in 2026 — and it also happens to be what good medicine for sensitive clients has always looked like.

The Bottom Line

Compounded GLP-1s are not categorically illegal, and they are not categorically fine. The difference lies entirely in why the compounded product exists for a specific client. Mass-market weight-loss compounding failed that test and is being shut down. Micro-dose therapy for MCAS and autoimmune clients — at strengths no manufacturer makes, with a hard stop when commercial doses are reached — is one of the few use cases the law was actually written to protect.

If you are a client living with MCAS, an autoimmune condition, or chronic inflammatory illness and want to explore whether carefully titrated low-dose GLP-1 therapy fits your situation, you can review membership options and fees at the practice fee schedule.

Disclaimer

The regulatory information in this article is gleaned from publicly available sources, including FDA guidance documents, Federal Register notices, and Texas State Board of Pharmacy materials, current as of the date of publication. I am a physician, not an attorney, and nothing in this article constitutes legal advice or a legal opinion. Laws, regulations, and enforcement policies in this area are evolving rapidly and may have changed since publication. Any prescriber or pharmacy considering compounded GLP-1 therapy should consult their own qualified healthcare attorney for a legal opinion specific to their practice, state licensure, and circumstances before implementing any protocol described here. This article is for educational purposes only and does not constitute medical advice; clients should discuss their individual situation with their own healthcare provider.

About Dr. Kim

Yoon Hang Kim, MD, MPH is board-certified in Preventive Medicine and Integrative & Holistic Medicine, with more than 20 years of clinical experience in integrative medicine. He completed fellowship training at the University of Arizona under Dr. Andrew Weil and holds certification in medical acupuncture (UCLA). His practice specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. Dr. Kim is the author of 3 books and more than 20 published articles.

Learn more at www.yoonhangkim.com | www.directintegrativecare.com